The TEVA PHARM ADR (TEVA) Position Lowered by TT International

The TEVA PHARM ADR (TEVA) Position Lowered by TT International

TT International lowered its position in shares of TEVA PHARM ADR (NYSE:TEVA) by 31.7% during the third quarter, Holdings Channel reports. The firm owned 938,594 shares of the company’s stock after selling 436,589 shares during the period. TEVA PHARM ADR makes up about 11.8% of TT International’s portfolio, making the stock its 2nd largest position. TT International owned approximately 0.10% of TEVA PHARM ADR worth $43,184,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Cheyne Capital Management UK LLP bought a new stake in shares of TEVA PHARM ADR during the second quarter worth $2,009,000. Bartlett & Co. LLC raised its stake in shares of TEVA PHARM ADR by 14.1% in the second quarter. Bartlett & Co. LLC now owns 4,526 shares of the company’s stock worth $227,000 after buying an additional 559 shares during the period. Argyle Capital Management Inc. raised its stake in shares of TEVA PHARM ADR by 10.7% in the second quarter. Argyle Capital Management Inc. now owns 37,502 shares of the company’s stock worth $1,884,000 after buying an additional 3,630 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of TEVA PHARM ADR by 6.2% in the second quarter. Cullen Frost Bankers Inc. now owns 10,838 shares of the company’s stock worth $545,000 after buying an additional 630 shares during the period. Finally, Diversified Trust Co raised its stake in shares of TEVA PHARM ADR by 20.4% in the second quarter. Diversified Trust Co now owns 57,607 shares of the company’s stock worth $2,894,000 after buying an additional 9,770 shares during the period. 54.53% of the stock is currently owned by hedge funds and other institutional investors.

TEVA PHARM ADR (NYSE:TEVA) opened at 34.10 on Thursday. TEVA PHARM ADR has a 52-week low of $33.56 and a 52-week high of $64.31. The company’s 50 day moving average is $36.11 and its 200-day moving average is $45.20. The stock has a market cap of $34.61 billion, a PE ratio of 19.84 and a beta of 0.65.

TEVA PHARM ADR (NYSE:TEVA) last announced its earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. The company earned $5.56 billion during the quarter, compared to analysts’ expectations of $5.71 billion. TEVA PHARM ADR had a net margin of 8.81% and a return on equity of 16.75%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.35 earnings per share. On average, equities analysts anticipate that TEVA PHARM ADR will post $5.12 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th were given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.99%. The ex-dividend date of this dividend was Thursday, December 1st. TEVA PHARM ADR’s dividend payout ratio is presently 67.44%.

Several research firms have commented on TEVA. Leerink Swann reaffirmed a “buy” rating on shares of TEVA PHARM ADR in a report on Friday, September 23rd. Mizuho reaffirmed a “buy” rating and issued a $64.00 price target on shares of TEVA PHARM ADR in a report on Monday, September 26th. OTR Global began coverage on shares of TEVA PHARM ADR in a report on Thursday, September 29th. They issued a “positive” rating on the stock. Wells Fargo & Co. reaffirmed a “buy” rating on shares of TEVA PHARM ADR in a report on Monday, October 3rd. Finally, Bank of America Corp. set a $72.00 price target on shares of TEVA PHARM ADR and gave the company a “buy” rating in a report on Saturday, October 1st. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $56.38.

TEVA PHARM ADR Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TEVA PHARM ADR (NYSE:TEVA).

Related posts

Leave a Comment